Campbell Alliance and BIO Release Two New Industry Reports on Deal-Making Trends at the 2011 BIO International Convention

June 29, 2011

Campbell Alliance and the Biotechnology Industry Organization (BIO) today released preliminary results of the 2011 Dealmakers’ Intentions Survey and the BIO Business Forum Partnering Report. Complete results of both studies will be presented during a Super Session at the 2011 BIO International Convention on Wednesday, June 29 from 2-3:30pm EDT. 

The Campbell Alliance Dealmakers’ Intentions Survey and the BIO Business Forum Partnering Report are the leading forward-looking measures of deal-making activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, these data offer a prospective view of the partnering and licensing landscape for the year ahead.

Now in its third year, the Campbell Alliance survey results represent input from all the major pharmaceutical markets and the analysis is split into four key areas, including Expectations, Valuation, Organization, and Strategic Implications. There were a number of interesting findings across all four of these areas:

  • Most dealmakers anticipate licensing activity to remain steady or grow in 2011
  • 50% of respondents expect an increase in early stage deals
  • Interest remains strong in oncology, CNS, and pain within the CNS category
  • Compared to 2010, there is about twice as much interest in 2011 in the areas of cardiovascular, metabolics, and dermatology

"The story behind the data is an important one this year. Traditional valuation models are certainly under pressure," stated Ben Bonifant, Practice Area Leader, Campbell Alliance. “Although many dealmakers anticipate an increasing number of deals, they also recognize several forces driving down valuations, including price, share of patients, discount rates, and the cost of clinical trials. This combination of factors has led some large pharma in-licensors to focus more on therapeutic areas and mechanisms that are traditionally more resistant to valuation challenges—those with niche patient populations. Ironically, those are the exact areas where an ambitious biotech management team can envision pursuing an independent commercialization strategy. The market dynamics are compelling.”

The BIO Business Forum Partnering Report provides an in-depth analysis of the more than 21,000 one-on-one meetings between more than 2,400 in-licensors and out-licensors in the Business Forum at the 2011 BIO International Convention, the world’s largest partnering event.

Highlights from the BIO Business Forum Partnering Report include:

  • Compared to 2010, there is a higher demand for Phase I assets as well as CNS, immunology metabolic therapeutic areas
  • In addition, the top three highest interest therapeutic areas in 2010 including CV, oncology and respiratory categories are now all in the bottom half of this year's top 10 areas

“Data extracted from BIO One-on-One PartneringTM can forecast deal-making trends and provide business leaders a unique perspective of the licensing environment,” said Dr. John Craighead, Managing Director, Investor Relations & Business Development at BIO. “Partnerships and collaborations are critical to the future of the biotechnology and pharmaceutical industries, and we were pleased to see a higher interest in earlier stage clinical programs.”

Access to the full results of the 2011 Dealmakers’ Intentions Survey and the BIO Business Forum Partnering Report are available on the BIO Industry Analysis Blog and Campbell Alliance website.

Complete results of both studies will be presented during a Super Session at the BIO International Convention on Wednesday, June 29, followed by a panel discussion involving senior industry executives.

Panelists for the Super Session include:

  • Ben Bonifant, Practice Area Leader, Campbell Alliance
  • John Craighead, Ph.D., Managing Director, Investor Relations and Business Development, BIO
  • Menelas Pangalos, Ph.D., Executive Vice President, Innovative Medicines, AstraZeneca
  • Doug Giordano, Senior Vice President, Worldwide Business Development, Pfizer Inc.
  • Maxine Gowen, Ph.D., President and Chief Executive Officer, Trevena
  • David Collier, M.D., Managing Director, Life Sciences, CMEA Capital

The 2011 BIO International Convention also hosts the BIO Business Forum, the world’s largest life sciences partnering event. With 190 company presentations and more than 20,000 one-on-one meetings expected, the BIO Business Forum plays a critical role in the development of collaborations to advance innovations that help heal, fuel and feed the world.

The BIO International Convention is the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers, and hundreds of sessions covering biotech trends, policy issues and technological innovations. For registration, conference agenda and exhibitor information, visit 2011 BIO International Convention.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit


Campbell Alliance
James Forte, 919-961-4066
Biotechnology Industry Organization
Tracy Cooley, 202-279-0536

inVentiv Health Consulting offers world class healthcare consulting services.

Media Contact:

Stephanie Koenig